SCHEMBL23249726

SCHEMBL23249726

CCc1c(C)nc(-n2nc(C)c(C)c2NC(=O)c2ccccc2Cl)[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.49
▸ POLB P06746 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TNKS2 Q9H2K2 1/20 0.40
▸ ADCY1 Q08828 4/20 0.40
▸ ADCY8 P40145 3/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HPGD P15428 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ DCTPP1 Q9H773 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23249507 0.86 ADCY8 (0.51) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249308 0.86 SLC2A1 (0.52) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249330 0.86 SLC2A1 (0.47) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249650 0.84 ADCY1 (0.49) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249699 0.84 SLC2A1 (0.67) SLC2A1POLBKMT2AMEN1ADCY1
SCHEMBL23249441 0.83 SLC2A1 (0.49) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249463 0.82 SLC2A1 (0.48) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249654 0.81 SLC2A1 (0.47) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23259342 0.81 SLC2A1 (0.47) SLC2A1POLBKMT2AMEN1TSHR
SCHEMBL23249633 0.81 SMN1; SMN2 (0.46) SLC2A1POLBKMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-02 — — US disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS TUBB, TUBB1, TUBA1C SLC2A1 4433/4885POLB 135/4885KMT2A 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback